The global urothelial cancer drugs market size is expected to
reach USD 3.6 billion by 2023, as per a new report by Grand View Research,
Inc., exhibiting a 22.9% CAGR during the forecast period. Availability of novel
drugs, presence of a strong pipeline, rising disease incidence, unhealthy
lifestyle, and increasing awareness are driving this market.
Urothelial cancer is the ninth most
common malignancy in the world, with approximately 2.5 million patients and
420,000 newly diagnosed cases each year. Approximately 59% of bladder cancer
cases occur in developed regions such as North America and Europe. The disease
has the highest lifetime cost of care per patient among all tumors in U.S. due
to its high relapse rate and invasive lifelong monitoring including cystoscopy
follow-ups.
Bladder transitional cell carcinoma
(TCC) is the most common histology, accounting for nearly 90% of all urinary
cancer cases. Urothelial cancer is clinically divided into three categories:
non-muscle invasive bladder cancer (NMIBC, early stage), muscle invasive
disease (MIBC, mid stage), and metastatic disease (late stage). At diagnosis,
approximately 70% of cases are non-muscle invasive disease, 20% are at the
muscle invasive stage, and 10% are at the advanced stage.
Browse full research report on Urothelial Cancer Drugs Market: https://www.grandviewresearch.com/industry-analysis/urothelial-cancer-drugs-market
Further key findings from the report suggest:
- The U.S. dominated the urothelial cancer market, with more
than 60% of the market in 2017. Several factors such as presence of a
large target population, increased adoption of novel therapeutics, and
multiple product launches will drive the market in this region
- The therapeutic landscape is expected to witness a paradigm
shift toward combination therapies and novel immuno-oncology products.
Combination regimens, particularly checkpoint inhibitors, are likely to be
introduced in the first-line setting. Immune checkpoint blockade therapy
is expected to replace the current standard of care in bladder cancer in
the foreseeable future
- Therapeutic development in second-line setting for
chemotherapy-intolerant patients is expected to have a major impact in the
urothelial cancer space
- Urothelial cancer presents a strong opportunity for
introducing first-in-class treatments due to high unmet needs.
Opportunities remain in the non-muscle invasive bladder cancer (NMIBC)
setting where there exists an unmet need for treatment options for
patients who are BCG-intolerant or ineligible
- Some of the key players operating in this market are Roche,
Merck, Bristol-Myers Squibb, AstraZeneca, and Pfizer.
Browse
request sample of this report by Grand View Research: https://www.grandviewresearch.com/industry-analysis/urothelial-cancer-drugs-market/request/rs1
Grand View Research has segmented the global urothelial cancer
drugs market based on treatment class and country:
Urothelial Cancer Drugs Treatment Class Outlook (USD Million, 2017
- 2023)
- Chemotherapy
- Immunotherapy
Urothelial Cancer Drugs Country Outlook (USD Million, 2017 - 2023)
- U.S.
- U.K.
- France
- Germany
- Italy
- Spain
- Japan
About
Grand View Research
Grand View Research, Inc. is a U.S.
based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides syndicated
research reports, customized research reports, and consulting services. To help
clients make informed business decisions, we offer market intelligence studies
ensuring relevant and fact-based research across a range of industries, from
technology to chemicals, materials and healthcare.
No comments:
Post a Comment